drugset / Trial / NCT00750334

A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)

NCT00750334

Phase 1 Terminated 2 enrolled Genzyme, a Sanofi Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.

Timeline

Start
2008-09
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified Oral